Kura Oncology, Inc. (KURA)
$9.83-5.48%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $873M
- Beta
- 0.38
- P/E (TTM)
- -2.85
- Short % float
- 16.77%
- Days to cover
- 7.7
- SI change
- -2.7%
- 1W
- -6.65%
- 1M
- -14.97%
- vs SPY 1W
- -6.51%
- vs SPY 1M
- -17.47%
Industry peers
FMP comparable companies · ranked by market cap
- HCMSELLHUTCHMED (China) Limited$2.5BRECOVERYQ 5$14.10-1.32%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.14%
- SLSSELLSELLAS Life Sciences Group, Inc.$2.2BRECOVERYQ -8$11.65+4.02%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.99-15.71%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-4.23%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 4$19.94-5.31%
- RIGLBUYRigel Pharmaceuticals, Inc.$908MBULLQ 9$49.08-3.42%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38-9.70%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 2
- VALUE
- 13
- GROWTH
- 17
- GARP
- 3
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-124.3%
REV YoY-
ROE-207.2%
EPS YoY-
ROA-50.5%
GROSS95
OP-412
NET-384
[VALUATION]
P/E TTM-2.85
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B17.63
P/FCF-
EV/EBITDA-2.75
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E50.49
ALTMAN Z-
CURR RATIO4.73
ND/EBITDA-
BETA0.38
Company news
FAQ
- What is LOPJLB’s current signal on KURA?
- LOPJLB’s latest quantitative signal on Kura Oncology, Inc. (KURA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is KURA in?
- Kura Oncology, Inc. (KURA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Kura Oncology, Inc. (KURA) do?
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted the…